Stocks Health care BLTE

NASDAQ · Health care

Belite Bio, Inc (BLTE)

It posted a net loss of $77.6M. In fiscal 2025 capital spending exceeded operating cash flow by $37.1M. At December 31, 2025 it held $352.9M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.

Watch BLTE in 60 seconds

Follow BLTE

Free, no password. An email when BLTE files with the SEC.

Key facts about Belite Bio, Inc

Net worth

Belite Bio, Inc has a market value (market cap) of $6.4B at the latest share price, and shareholders' equity of $770.5M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $37M of cash.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 31, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What Belite Bio, Inc does

Belite Bio, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BLTE.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Belite Bio, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 19, 2026
   Foreign issuer update 6-K
2. September 8, 2026
   Foreign issuer update 6-K
3. August 13, 2026
   Foreign issuer update 6-K
4. August 11, 2026
   Foreign issuer update 6-K
5. June 15, 2026
   Foreign issuer update 6-K
6. May 20, 2026
   Foreign issuer update 6-K
7. May 14, 2026
   Passive stake changed SCHEDULE 13G/A
8. April 21, 2026
   Foreign issuer update 6-K
9. March 31, 2026
   Foreign issuer update 6-K
10. March 31, 2026
    Annual report (foreign issuer) 20-F · period to December 31, 2025Diluted EPS -$2.31 versus -$1.18.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 30, 2026. Insider transactions on SEC

Insider trades

What the people running Belite Bio, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $32M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BLTE

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Yu-Hsin Lin 3.1% (May 14, 2026).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 81 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 525,240 shares in total, about $82.8M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BLTE

What does Belite Bio, Inc do?

Belite Bio, Inc is a company in the Health care sector, listed on NASDAQ as BLTE. Its shares trade on NASDAQ under the ticker BLTE.

What is Belite Bio, Inc's net worth?

Belite Bio, Inc has a market value (market cap) of $6.4B at the latest share price, and shareholders' equity of $770.5M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Belite Bio, Inc profitable?

No. In fiscal 2025 it reported a net loss of $77.6M.

When did Belite Bio, Inc last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from October 30, 2026.

Similar companies

Compare BLTE with

Compare BLTE with any company

Follow BLTE

Get an email when Belite Bio, Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow BLTE

Free, no password. An email when BLTE files with the SEC.

Where the numbers come from

Financial figures are the values Belite Bio, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.